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ABSTRACT
Tumor necrosis factor–alpha (TNF-) antagonist therapy has proven effective in inflammatory conditions such
as rheumatoid arthritis and Crohn’s disease. There is substantial evidence that TNF- also plays a role in the
development of graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation, which
along with leukemia relapse remains one of the 2 major impediments to success of the approach. Using a
recently developed potent rat/mouse chimeric monoclonal antibody directed against murine TNF-
(CNTO2213), the authors investigated the effect of TNF- blockade on GVHD mediated by either CD4 or
CD8 donor T cells. The results indicated that the treatment had only a moderate effect on both a CD8 T
cell–mediated major histocompatibility complex–matched GVHD model involving multiple minor histocom-
patibility antigens and a p3F1 acute GVHD model directed against a haplo-mismatched major histocompat-
ibility complex barrier involving both CD4 and CD8 T cells. In contrast, treatment with the anti–TNF-
antibody had a highly significant effect (100% survival rate) on the CD4 T cell–mediated component of this
latter model. Importantly, anti–TNF- antibody did not block the development of a graft-versus-leukemia
effect against a murine myeloid leukemia challenge in either a syngeneic or allogeneic p3F1 setting. This
suggests that the inhibition of TNF- during allogeneic hematopoietic cell transplantation may be able to
diminish the inflammatory GVHD reaction without hindering effective graft-versus-leukemia responses.
© 2003 American Society for Blood and Marrow Transplantation
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INTRODUCTION
Allogeneic hematopoietic cell transplantation
(HCT), using bone marrow, umbilical cord blood, or
mobilized peripheral blood as the source of stem cells
is a clinical treatment for several malignant and non-
malignant diseases, including acute and chronic leu-
kemias, myelomas, and severe immunodeﬁciencies
[1-3]. In those patients being treated for leukemia, the
success of HCT is signiﬁcantly limited by the compli-
cations of graft-versus-host disease (GVHD) and leu-
kemia relapse. Depletion of mature T cells from the
donor inoculum reduces the incidence and severity of
acute GVHD. However, T cell depletion also in-
creases the risk of leukemia relapse, suggesting that
alloreactive donor T cells may mediate both GVHD
and the graft-versus-leukemia (GVL) effect [4-6].
Thus, the development of approaches to separate
GVL responses from GVHD immunopathogenesis is
a major focus of research in the allogeneic HCT ﬁeld.
It is now well accepted that a cascade of cytokines
is involved in the induction and maintenance of
GVHD [7]. The inﬂammatory cytokine, tumor necro-
sis factor–alpha (TNF-) can be involved in at least 3
phases of acute GVHD. First, during intensive trans-
plant conditioning, host endothelium and epithelium
in the intestine, skin, and liver can be damaged. This
damage can lead to activated host cells that secrete
TNF- and interleukin (IL)-1. These cytokines, in
turn, can upregulate major histocompatibility complex
(MHC) antigens and adhesion molecules that will
enhance the recognition of host MHC or minor his-
tocompatibility antigens (miHA) by mature donor T
cells present in the donor HCT inoculum [8,9].
In the second phase, the activated donor T cells
begin to differentiate and proliferate [7]. As they do,
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cytokines (predominantly the TH1-related interferon
gamma [IFN-] and IL-2) act to amplify the response
even further by inducing cytotoxic T lymphocyte
(CTL) and natural killer (NK) cell responses and by
priming donor and residual host macrophages to pro-
duce TNF-. In turn, TNF- released from both T
cells and activated macrophages induce the produc-
tion of chemokines, such as macrophage inﬂammatory
protein–1 and monocyte chemoattractant protein–1,
that function to recruit cells to inﬂammatory sites.
TNF- also upregulates the expression of intercellu-
lar adhesion molecules–1 on vascular endothelium,
which enhances the ability of T cells and other leu-
kocytes to extravasate into GVHD target tissues
[10,11].
During the third phase of acute GVHD, massive
tissue destruction is found but is not only mediated by
CTL and NK cells. Monocytes may encounter endo-
toxin (lipopolysaccharide) that has leaked through the
conditioning regimen–damaged intestinal wall and
may be triggered to secrete large amounts of TNF-.
TNF- can then directly contribute to tissue damage
by inducing apoptosis, or even necrosis, of target cells.
TNF- may synergize with the cellular damage
caused by CTL and NK cells and further amplify
tissue destruction and the inﬂammatory response
[10,12]. These combined pathologic effects could then
result in the clinical symptoms of GVHD.
Anti-TNF therapies have proved successful in the
treatment of inﬂammatory diseases, such as rheuma-
toid arthritis [13] and Crohn’s disease [14]. These
approaches seek to bind TNF- or to block the in-
teraction of TNF- with its receptors thereby inhib-
iting its biological effects. In this regard, inﬂiximab, a
mouse/human Fc chimeric IgG1 monoclonal anti-
body (mAb) speciﬁc for human TNF-, has exhibited
clinical efﬁcacy as an inﬂammatory inhibitor [15], and
its applicability to the treatment or prevention of
GVHD currently is under consideration.
Early evidence from clinical studies in HCT indi-
cated that the systemic release of TNF- during pre-
transplant conditioning correlated with poor out-
comes [16]. In other studies examining the
posttransplant period, it was found that TNF- sig-
niﬁcantly increased in the second to third week, and
the high levels correlated with developing acute
GVHD as well as with other acute endothelial com-
plications [17-20]. Based on these ﬁndings, clinical
trials were initiated with anti–TNF-&rtf-space; mAb
posttransplant and resulted in some success in the
inhibition of GVHD pathology, particularly in the
skin and gut, but overall they were limited by short-
term administration and problems with the immuno-
genicity of the reagents [21-23]. Holler et al. [24] also
tested prophylactic neutralization of TNF- during
the course of pretransplant conditioning and found
that it could reduce the levels of TNF-, and subse-
quently the severity and onset of acute GVHD.
Over the last 15 years, the effect of anti–TNF-
antibodies on development of GVHD in experimental
models has been somewhat varied, partially because of
the varied reagents involved in the studies. Piguet et
al. [25] were the ﬁrst to show the involvement of
TNF- in GVHD, using a P3F1 model of MHC-
incompatible HCT. Lethally irradiated mice were in-
jected with T cell–depleted bone marrow and lymph
node T cells to induce GVHD, and it was found that
a weekly treatment with a neutralizing rabbit anti-
mouse recombinant TNF- IgG polyclonal antibody
reduced the incidence of skin and gut lesions associ-
ated with GVHD and decreased mortality rate. Other
groups have conﬁrmed these observations by admin-
istering various types of anti–TNF- antibody prep-
arations or inhibitors, starting either before HCT or
within the ﬁrst week after transplant [26-32]. How-
ever, in some models, TNF- blockade did not seem
to have much of an effect [33].
In the current study, we have sought to investigate
the potential of a recently generated rat/mouse Fc
chimeric IgG2a mAb (CNTO2213) equivalent of in-
ﬂiximab, directed against murine TNF-, to inhibit
GVHD. Of particular interest, we wanted to test its
effectiveness in both CD4- and CD8-mediated
GVHD development and whether it was capable of
inhibiting GVHD while retaining a GVL effect
against a myeloid leukemia challenge. The results in-
dicated that anti–TNF-mAb treatment from day1
to day 12 post-HCT had a moderate effect in a CD8-
mediated GVHDmodel involving multiple miHA dif-
ferences and an equally moderate effect in a model
directed across an MHC barrier when both CD4 and
CD8 donor T cells were transplanted. However, the
anti–TNF- mAb treatment had a highly signiﬁcant
effect (100% survival rate) on the isolated CD4-me-
diated GVHD component in this latter MHC dispar-
ate model. In addition, treatment with anti–TNF-
mAb within the ﬁrst 3 weeks of a syngeneic or allo-
geneic donor transplant of bone marrow and T cells
did not block the development of a GVL effect against
a myeloid leukemia challenge. These results suggest
that controlling the levels of TNF- during allogeneic
HCTmay be able to limit the development of GVHD
while still allowing the generation of GVL responses.
MATERIALS AND METHODS
Mice
Male C3H/HeJ (C3H; H2k), (B6xC3H)F1
(H2bxk), (B6xDBA/2)F1 (H2
bxd), C57BL/6 (B6; H2b),
and CBA/JCr (CBA; H2k) mice were purchased from
the National Cancer Institute Research and Develop-
ment Center (Frederick, MD). B10.BR (H2k) mice
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were purchased from the Jackson Laboratories (Bar
Harbour, ME). Mice used for experiments were be-
tween 6 and 10 weeks of age and were housed in sterile
microisolator cages within a speciﬁc pathogen-free
facility, receiving autoclaved food and water ad libi-
tum.
Cell Line
MMB3.19, a c-myc–transformed myeloid leukemia
line, was originally cloned from the ascites of a B6
mouse that had been injected with a myc-encoding
Moloney murine leukemia virus construct as previ-
ously described [34,35].
Media
Phosphate-buffered saline (PBS) supplemented
with 0.1% bovine serum albumin (BSA) (Sigma
Chemical Co, St Louis, MO) was used for all in vitro
manipulations of the donor bone marrow and lym-
phocytes. Immediately before injection, the cells were
washed and resuspended in PBS alone. For maintain-
ing cell lines and for in vitro assays, RPMI 1640
medium (Mediatech, Herndon, VA) was used, supple-
mented with 10% fetal bovine serum (FBS; GIBCO,
Grand Island, NY), 2 mmol/L L-glutamine, 50
IU/mL penicillin,and 50 g/mL streptomycin.
Antibodies
The CNTO2213 mAb, a rat/mouse Fc chimeric
IgG2a construct with rat (Fab)2 units speciﬁc for mu-
rine TNF- [36] (tissue culture derived and puriﬁed
with protein A) and its isotype control CNT0412, a
human anti-CD4 mAb, were provided by Centocor
(Malvern, PA). Ascites ﬂuid containing mAb (5 to 10
mg/mL) were generated from hybridoma lines speciﬁc
for Thy-1.2 (J1j; ATTC TIB-184), CD4 (RL172;
[37]), or CD8 (3.168; [38]) proteins, and were used for
the preparation of cellular grafts. Afﬁnity-puriﬁed
goat antimouse IgG (Cappel, Cosa Mesa, CA) was
used for B cell depletion. Guinea pig complement was
purchased from Rockland Immunochemicals (Gil-
bertsville, PA). Anti-CD3, anti-CD4, anti-CD8, anti-
B220, and isotype control mAb, all coupled to phyco-
erythrin, were all purchased from BD Biosciences
(Palo Alto, CA).
Bone Marrow Transplantation
As previously described [39], bone marrow was
harvested from the tibia and femurs of donor mice by
ﬂushing with PBS containing 0.01% BSA (PBS/BSA).
Bone marrow cells were depleted of T cells using an
anti-Thy 1.2 mAb (J1j; ATCC) at a 1:100 dilution and
guinea pig complement (Rockland Immunochemicals,
Gilbertsville, PA) at a dilution of 1:6 for 45 minutes at
37°C. Lymphocytes were isolated from spleens and
lymph nodes of donor mice. Splenocytes were treated
with Gey’s balanced salt lysing solution containing
0.7% ammonium chloride (NH4Cl) to remove red
blood cells. After red blood cell depletion, spleen and
lymph node cells were pooled and depleted of B cells
by panning on a plastic petri dish, precoated with a 5
g/mL dilution of goat anti-mouse IgG for 1 hour at
4°C. These treatments resulted in donor populations
of 90% to 95% CD3 cells, as quantitated by ﬂuo-
rescent ﬂow cytometry. T cells subsets were then
isolated via negative selection using either anti-CD8
(3.168, 1:50 dilution) or anti-CD4 mAb (RL172,
1:100 dilution) and complement. These treatments
reduced the targeted T cell subset populations to
background levels as determined by ﬂow cytometric
analysis. Recipient mice were exposed to 13 Gy whole
body irradiation from a Mark-I-68A 137Cs source (JL
Shepherd, San Fernando, CA) at 1.43 Gy/min, deliv-
ered in a split dose of 6.5 Gy each, separated by 3
hours. These mice were then transplanted with 2 
106 anti-Thy 1.2–treated bone marrow cells (ATBM;
T cell-depleted) along with the indicated number of
appropriate T cells (donor CD4 or CD8 enriched T
cells), intravenously (iv) via the tail vein. Mice were
treated with CNTO2213 anti–TNF- or isotype con-
trol CNTO412 mAbs (1 mg; intraperitoneally [ip])
one day before transplantation and again on days 0, 4,
8, and 12 (all at 0.5 mg; ip). For GVL experiments, B6
recipient mice were challenged with an injection of
MMB3.19 cells (1  105in 0.5 mL PBS; ip) one day
before transplantation of donor ATBM and T cells,
with a similar schedule of anti–TNF- mAb treat-
ment. In both GVHD and GVL experiments, the
mice were checked daily for morbidity and mortality
until completion. As indicated, the data were pooled
from 2 to 3 separate experiments, and median survival
times (MST) were determined as the interpolated
50% survival point of a linear regression through all of
the day of death data points and including zero. Sta-
tistical comparisons for survival between experimental
groups were performed by the nonparametric Wil-
coxon signed rank test. Signiﬁcance for weight com-
parisons was determined by the t test at individual
time-points.
Flow Cytometry
Appropriate mAbs in volumes of 25 L were in-
cubated with 2 to 5 105 cells in the wells of a 96-well
U-bottom microplate at 4°C for 30 minutes, centri-
fuged at 1500 rpm for 3 minutes, and washed with
PBS containing 0.1% BSA and 0.01% sodium azide
(wash buffer). The ﬂuorescence analysis was per-
formed on an EPICS Proﬁle II analyzer (Coulter,
Hialeah, FL) in the Kimmel Cancer Institute Flow
Cytometry Facility, at Thomas Jeffeson University in
Philadelphia. The percentage of positive cells and the
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arithmetic mean ﬂuorescence intensity were calcu-
lated for each sample.
Serum Cytokine Measurements
Blood was collected via the tail vein, allowed to
clot overnight at 4°C, and centrifuged at 10,000 rpm
for 30 minutes at 4°C. Serum was collected and
pooled from groups of 5 mice in each treatment
group. The Cytometric Bead Array (BD Biosciences)
was used to measure serum levels of TNF-, IFN-,
and IL-5. Brieﬂy, polystyrene beads, dyed to emit
unique ﬂuorescent intensities and coupled to speciﬁc
mAb against each of the 3 cytokines, served as capture
reagents. Cytokines were detected simultaneously in a
mixture via direct immunoassay containing 50 l of
test sample, 10 l of each mouse cytokine capture
mAb-bead reagent and 50 l of cytokine-speciﬁc phy-
coerythrin -coupled mAb used as a detection reagent.
Standard curves were obtained using sets of calibrators
ranging from 0 to 5000 pg/mL for each cytokine in
the mixture. The mixtures were incubated for 2 hours
in the dark at room temperature and washed to re-
move unbound phycoerythrin -detection reagent be-
fore data acquisition using ﬂow cytometry. The con-
centration of IL-6 in serum was determined via a
commercial ELISA kit (R & D Systems, Inc, Minne-
apolis, MN), calibrated using an IL-6 standard pro-
vided in the kit, and performed on triplicate samples.
Pathologic Analysis
Full-thickness ear biopsies were sampled from
each mouse of the various treatment groups and im-
mediately placed in 10% phosphate buffered formalin
and ﬁxed for at least 24 hours before processing. The
samples were then dehydrated through graded alco-
hols and xylene and embedded in parafﬁn. Sections
were cut at 6 m and stained with H& E. Histopatho-
logic examination was performed using a standard
light microscope with a 40X objective and a 10X
ocular lens. The analysis was performed under blinded
conditions as to treatment groups. The mean number
of dyskeratotic epidermal cells per linear millimeter
was determined, as previously [40], by counting the
dyskeratotic cells (ie, pyknotic nucleus surrounded by
an eosinophilic cytoplasm) and total epidermal length
in millimeters (minimum 10 mm per tissue section),
measured for 3 to 4 separate tissue sections per animal
and then averaged. The mean value was then calcu-
lated from these averages with 3 animals per group.
RESULTS
Effect of Anti–TNF- mAb on CD8 T
Cell-Mediated GVHD
To determine if anti–TNF- mAb treatment
could affect the development of CD8 T cell–medi-
ated GVHD, the MHC-matched, miHA-disparate
B10.BR3CBA GVHDmodel was utilized with a well
established etiology [41]. CBA mice were irradiated
lethally (13 Gy, split dose) and transplanted with
B10.BR ATBM cells (2 106), alone, or in addition to
a highly enriched population (95%) of CD8 T cells
(3  106). Mice were left either untreated or treated
with the isotype-matched control CNTO412 or anti–
TNF- mAbs on day 1 (1 mg, ip) and days 0, 4, 8,
and 12 of transplant (0.5 mg; ip). Whereas all recipi-
ents of ATBM cells alone survived for at least 70 days,
as expected, mice transplanted with donor T cells and
left untreated or treated with control CNTO412 mAb
all succumbed to GVHD with similar MST values of
21.5 and 29.1 days, respectively (P 0.59; Figure 1A).
In contrast, CBA recipients of donor T cells that were
administered anti–TNF- mAb, exhibited a 42.9%
survival rate with an MST of 48.4 days (P  0.018 in
comparison with the CNTO412 control group). In
Figure 1. Effect of anti–TNF- mAb on CD8 T cell–mediated
GVHD. CBA mice were lethally irradiated (13 Gy, split dose) and
transplanted with B10.BR ATBM cells (2  106), alone or in
addition to a highly enriched population (95%) of CD8 T cells
(3  106). Mice were either left untreated, treated with control
CNTO412 mAb, or the anti–TNF-mAb on day1 (1 mg, ip) and
days 0, 4, 8, and 12 of transplant (0.5 mg; ip). A, percent survival
posttransplant. MST values (days) were untreated (21.5; n  3);
CNTO412 (29.1; n  7); and anti–TNF- mAb (48.4; n  8; P 
.018 v CNTO412). Results represent pooled data from 2 similar
experiments. B, mean 	 SEM % initial body weight; pooled data
(same as in A).
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addition, surviving anti–TNF- mAb-treated mice
did not display evident symptoms of GVHD (eg, ruf-
ﬂed fur, skin lesions, hunched posture, or diarrhea),
and their body weights were at a relatively constant
level ranging 5% to 12% below that of the control
ATBM transplanted group (with no signiﬁcant differ-
ence; P .17, on days 6 to 32, and P  .05 on day 49;
Figure 1B). Mice that did develop fatal GVHD in the
presence of anti–TNF- mAb seemed to do so with
slower kinetics than the untreated or CNTO412-
treated groups.
Effect of Anti–TNF- mAb on GVHD across
an MHC Barrier
The haploidentical C3H3(B6xC3H)F1 mouse
model was utilized to determine whether the neutral-
ization of TNF- by mAb treatment could affect the
course of GVHD across a full MHC barrier. C3H T
cells (both CD4 and CD8; 5  106) and ATBM
cells (2 x 106) were transplanted iv into lethally
irradiated (13 Gy, split dose) (B6xC3H)F1 mice, which
induced a rapid acute GVHD response characterized
by severe weight loss and early fatality (MST of 5.3
days; Figures 2A and B). Similar results were obtained
in recipients treated with control CNTO412 mAb,
but those mice treated with anti–TNF- mAb (1 mg
ip on day 1 and 0.5 mg on days 0, 4, 8, and 12)
exhibited a 40% long-term survival rate with an MST
of 40.9 days (P .001 compared with either untreated
or the CNTO412 control groups).
In terms of weight loss, after an initial slight drop
in the ﬁrst few days caused by the irradiation condi-
tioning, the control ATBM mice steadily gained
weight throughout the remainder of the experiment
(Figure 2B). However, the untreated and CNTO412-
treated groups transplanted with donor T cells never
recovered from the initial drop and instead continued
to rapidly lose weight until their death, consistent with
severe GVHD. However, the anti–TNF- mAb-
treated mice began to recover by day 9, and surviving
animals after day 37 continued to gain weight during
the remaining course of the experiment, tracking ap-
proximately 6% to 12% below the ATBM group (P 
.02 at all time points).
Effect of Anti–TNF- mAb on CD4
T-Cell–Mediated GVHD
Because donor CD4 T cell responses tend to
dominate the development of GVHD in the
C3H3(B6xC3H)F1model [35], and in light of the
initial observation of a moderate effect of anti–TNF-
mAb treatment when a complete donor T cell inocu-
lum was transplanted, we focused our attention on the
CD4-mediated GVHD component. The injection of
3  106 C3H CD4 T cells together with 2  106
ATBM cells into irradiated (13 Gy, split dose)
(B6xC3H)F1 mice resulted in the majority of the un-
treated (75%; MST of 26.5 days) and control
CNTO412-treated (81.3%; MST of 13.5 days) mice
succumbing to severe acute GVHD (Figure 3A). In
contrast, 100% of the mice treated with the anti–
TNF- mAb (1 mg ip on day 1 and 0.5 mg on days
0, 4, 8, and 12) survived beyond 60 days (P  .001).
These mice did not exhibit any visible symptoms of
GVHD and rapidly recovered from their initial body
weight loss after irradiation and continued to gain
weight until the end of the experiment in parallel to
the ATBM control group (no signiﬁcant difference by
day 58; P  .12; Figure 3B). The highly signiﬁcant
effect of anti–TNF- mAb treatment on survival in
the CD4-mediated GVHD suggested that the more
modest effect observed previously with transfer of a
whole donor T cell inoculum (Figure 1A) was likely
owing to less inhibition of CD8-mediated anti-MHC
Figure 2. Effect of anti–TNF- mAb on GVHD across an MHC
barrier. (B6xC3H)F1 mice were lethally irradiated (13 Gy, split
dose) and transplanted iv with C3H ATBM cells (2  106), alone,
or in addition to T cells (5  106). Mice were either left untreated,
treated with control CNTO412 mAb, or the anti–TNF- mAb on
day 1 (1 mg, ip) and days 0, 4, 8, and 12 of transplant (0.5 mg; ip).
A, percent survival posttransplant. MST values (days) were un-
treated (5.3); CNTO412 (5.8); and anti–TNF- mAb (40.9; P 
.001 v CNTO412 or untreated). Results represent pooled data (n
15 per group) from 3 similar experiments. B, mean	 SEM% initial
body weight; pooled data (same as in A).
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class I responses. However, this could not be tested
directly in this model, because puriﬁed C3H CD8 T
cells were unable to mediate lethal GVHD on their
own without the presence of CD4 T cells.
Pathologic Analysis after Anti–TNF- mAb
Treatment
Sequential pathologic samples were prepared from
the ear skin of mice in the CD4 T cell–mediated
C3H3(B6xC3H)F1 model, treated with anti–TNF-;
or CNTO412 mAbs, as above. Dyskeratotic cells (ap-
optotic keratinocytes) are a useful diagnostic measure
of the severity of GVHD in that their increased pres-
ence in epithelial layers correlates well with the sever-
ity of disease [40]. In the initial stage of GVHD (day
6), there was a signiﬁcant difference in the mean
number of dyskeratotic cells per millimeter of epithe-
lial tissue between the CNTO412-treated and the
anti–TNF-; mAb-treated groups (0.95 v 0.16 cells
per millimeter, respectively; P  .001; Figure 4). Rep-
resentative epithelial tissue samples from these 2
groups showed the discord in dyskeratotic cell num-
bers (Figures 5A and B), with almost none observed in
any given ﬁeld of the anti–TNF-; mAb-treated tis-
sue. Also notable was that there was no signiﬁcant
difference between the anti–TNF-; mAb-treated and
the control ATBM groups on day 6 (0.16 v 0.11
dyskeratotic cells per millimetre; P  .11), and this
lack of signiﬁcance persisted on days 15 and 30 post-
transplantation (P  .08; Figure 4). On day 45, al-
though both groups were still declining in number,
the anti–TNF- mAb-treated group was found to be
signiﬁcantly higher than the ATBM control (P 
.001). No comparison could be made with the control
CNTO412-treated group at these later time-points
because those mice had all succumbed to GVHD
before day 15.
Serum Cytokine Concentrations after Anti–TNF-
mAb Treatment
The concentrations of TNF-, IFN-, IL-5 and
IL-6 were measured in the pooled sera of mice at
various time points (days 1 to 11) during the
course of GVHD in the CD4 T cell–mediated
C3H3(B6xC3H)F1 model. Mice were treated with
anti–TNF- or CNTO412 mAbs, as per the schedule
used previously, with 1 mg ip on day 1 and 0.5 mg
on days 0, 4, and 8 (the only difference being the lack
of injection on day 12). Anti-TNF mAb-treated mice
exhibited a signiﬁcant reduction in circulating TNF-
on days 6 and 7 (76 and 83 pg/mL, respectively)
Figure 4. Summary of cutaneous GVHD pathologic effects after
anti–TNF- mAb treatment. Sequential pathologic samples were
prepared from the ear skin of mice in the CD4 T cell–-mediated
C3H3(B6xC3H)F1 model, treated with anti–TNF- or
CNTO412 mAb, as described in Figure 3. The mean 	 SEM
number of dyskeratotic cells per millimeter of epithelial tissue were
calculated as described in Materials and Methods for 3 samples each
group.
Figure 3. Effect of anti–TNF- mAb on CD4 T cell–mediated
GVHD. (B6xC3H)F1 mice were lethally irradiated (13 Gy, split
dose) and transplanted iv with C3H ATBM cells (2  106), alone,
or in addition to a highly enriched population (
98%) of CD4 T
cells (5  106). Mice were left untreated or treated with control
CNTO412 or the anti–TNF- mAb on day 1 (1 mg, ip) and days
0, 4, 8, and 12 of transplant (0.5 mg; ip). A, percent survival
posttransplant. MST values (days) were untreated (26.5);
CNTO412 (13.5); and anti–TNF- mAb (
60; P  .001 v
CNTO412 or untreated). Results represent pooled data (n 15 per
group) from 2 similar experiments. B, mean 	 SEM % initial body
weight; pooled data (same as in A).
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compared with the control CNTO412-treated group
(224 and 365 pg/mL, respectively; Figure 6A). TNF
levels had been decreased to nearly background levels
on these days when compared with the control ATBM
group and remained that way even on day 11 post-
transplantation, by which time all CNTO412-treated
mice had died. There was also a signiﬁcant reduction
in the levels of circulating IFN- in the anti–TNF-
mAb-treated group (ranging from 55 to 70 pg/mL) as
seen on days 5 through 7 posttransplantation, com-
pared with 154 to 331 pg/mL observed in the
CNTO412-treated group (Figure 6B). IFN- levels
were, however, still highly increased over that seen in
the control ATBM mice. In contrast, IL-6 levels were
only slightly decreased in comparison with the
CNTO412-treated group on days 6 and 7 of GVHD
but were clearly elevated (370 to 390 pg/mL) above
the background levels (75 to 80 pg/mL) obtained in
the ATBM mice (Figure 6C). IL-5 levels did not seem
to be affected by treatment with anti–TNF- mAb
and were equivalent to the elevated levels (44 to 52
pg/mL) found in the CNTO412-treated mice (Figure
6D).
Effect of Anti–TNF- mAb Treatment on
Syngeneic GVL Activity
The effectiveness of the anti–TNF- mAb treat-
ment in CD4-mediated GVHD raised the question of
whether the neutralization of this inﬂammatory cyto-
kine would also diminish the capacity of donor T cells
to mediate a GVL response. To address this issue, we
initially investigated a syngeneic B6 GVL bone mar-
row transplant model involving a mouse myeloid leu-
kemia line (MMB3.19) that had been previously used
in our laboratory [35]. B6 mice were irradiated (10
Gy) and transplanted with B6 ATBM cells (2  106)
alone, or in combination with 2  107 CD4 T cells
from donor B6 mice that had been presensitized to
MMB3.19 (ip immunization with 30 Gy–treated tu-
mor cells 3 weeks before transplantation). These mice
were then challenged with an ip injection of 7.5 – 104
MMB3.19 leukemia cells on day one. Next, mice were
either left untreated or treated with anti–TNF- or
control CNTO412 mAbs (1 mg on day 1 ip; 0.5 mg
on days 0 to 24, every 4th day). We extended the
period of treatment to ensure that it would overlap
with the GVL response. Mice given only ATBM and
challenged with the MMB3.19 cells all succumbed to
tumor burden with most fatalities occurring by day 21
posttransplantation with an MST of 16.7 days (Figure
7). However, mice given the donor CD4 T cell
inoculum and left untreated or treated with
Figure 5. Histologic identiﬁcation of apoptotic target epidermal
cells in murine ear skin 6 days posttransplant. Tissue was sampled
from mice described in Figure 3. As compared with CNTO412
mAb-treated recipients of C3H CD4 T cells (A; arrows indicate
apoptotic basal cells), skin of anti–TNF-; mAb-treated recipients
(B) contained only rare apoptotic cells and resembled skin of ATBM
alone recipients. (Original magniﬁcation x40.)
Figure 6. Serum cytokine concentrations after anti–TNF- mAb
treatment. The concentrations of TNF-, IFN-, IL-5, and IL-6
were measured in the pooled sera of mice at various time points
(days 1 to 11) during the course of GVHD in the CD4 T
cell–mediated C3H3(B6xC3H)F1 model. Mice were treated with
anti–TNF- or CNTO412 mAbs; 1 mg ip on day 1 and 0.5 mg
on days 0, 4, and 8. Serum from 5 mice per group were pooled and
analyzed for the following cytokines: A, TNF- levels; B, IFN-; C,
IL-6; D, IL-5. , ATBM; , CNT0412; , Anti-TNF mAb.
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CNTO412 mAb were able to mediate a GVL effect
and prolong survival with MSTs of 25.3 and 25.2 days,
respectively. Of most importance, mice treated with
anti–TNF- mAb displayed a signiﬁcant increase in
survival time because of their syngeneic GVL capacity
compared with the ATBM plus MMB3.19 control
group (P .03), with an MST of 23.8 days, equivalent
to that observed in the untreated (P  .60) and
CNTO412-treated (P 
 0.72) CD4 T cell groups.
Thus, the same anti–TNF- mAb treatment that ef-
fectively blocked the development of CD4 T cell–
mediated GVHD (as shown above) did not seem to
affect the capacity of CD4 T cells to mediate anti-
myeloid leukemia responses in an environment that
lacked alloreactivity.
Effect of Anti–TNF- mAb Treatment on
Allogeneic GVL Activity
The most important question was whether the
CNTO2213 anti–TNF- mAb treatment in the
CD4-mediated GVHD model could block disease de-
velopment while still being permissive for the GVL
response in the allogeneic setting. As in previous ex-
periments, (B6xC3H)F1 mice were irradiated (13 Gy,
split dose) and transplanted with C3H ATBM cells
(2  106) alone, or in combination with 3  106 naı¨ve
C3H CD4 T cells. These mice were then challenged
with an ip injection of 7.5  104 MMB3.19 leukemia
cells (completely allogeneic to the donor C3H cells)
on day one, and mice were either left untreated or
treated with anti–TNF- or control CNTO412 mAbs
(1mg on day 1 ip; 0.5 mg on days 0 through 24,
every 4th day). All of the mice given only ATBM and
challenged with the MMB3.19 cells succumbed to
tumor burden, with an MST of 24.2 days (Figure 8).
Mice transplanted with ATBM and donor CD4 T
cells without MMB3.19 challenge succumbed to acute
GVHD with an MST of 6.8 days. Similarly, trans-
planted mice with MMB3.19, and left untreated or
treated with CNTO412 mAb, also died of GVHD
with MSTs of 10.7 and 6.7 days, respectively, as would
still be expected because of the antihost alloreactivity.
In contrast, those mice receiving ATBM, CD4 T
cells, and challenge with MMB3.19 leukemia, fol-
lowed by anti–TNF- mAb treatments, avoided the
early GVHD fatality and were able to mediate a GVL
effect. Survival of this group was prolonged with an
MST of 32.1 days and was signiﬁcantly longer than
the ATBM mice given MMB3.19 cells alone (P 
.002). Mice mortality in the anti–TNF- mAb group
appeared to be caused by tumor burden, because they
did not exhibit symptoms of GVHD, and leukemia
cells were evident in the peritoneum at autopsy. In an
Figure 7. Effect of anti–TNF-mAb treatment on syngeneic GVL
activity. B6 mice were irradiated (10 Gy) and transplanted with B6
ATBM cells (2 106) alone, or in combination with 2 107 CD4
T cells from donor B6 mice that had been presensitized to
MMB3.19. These mice were then challenged with an ip injection of
7.5  104 MMB3.19 cells on day one. Mice were either left un-
treated or treated with anti–TNF- or control CNTO412 mAbs
(1mg on day 1 ip; 0.5 mg on days 0 to 24, every 4th day). MST
values (days) were: ATBM plus MMB3.19 (16.7); ATBM plus
CD4 plus MMB3.19 (25.3); ATBM plus CD4 plus MMB3.19
plus CNTO412 (25.2); ATBM plus CD4 plus MMB3.19 plus
anti–TNF-mAb (23.8; P .029 v ATBM plus MMB3.19; P
 .72
v CNTO412). The results represent pooled data (n 16 per group)
from 3 similar experiments.
Figure 8. Effect of anti–TNF-mAb treatment on allogeneic GVL
activity. (B6xC3H)F1 mice were irradiated (13 Gy, split dose) and
transplanted with C3H ATBM cells (2  106) alone, or in combi-
nation with 3  106 naı¨ve C3H CD4 T cells. These mice were
then challenged with an ip injection of 7.5 104 MMB3.19 cells on
day 1, and mice were either left untreated or treated with anti–
TNF- or control CNTO412 mAbs (1mg on day 1 ip; 0.5 mg on
days 0 to 24, every 4th day). MST values (days) were: ATBM plus
MMB3.19 (24.2); ATBM plus CD4 (6.8); ATBM plus CD4 plus
MMB3.19 (10.7); ATBM plus CD4 plus MMB3.19 plus CNTO412
(6.7); ATBM plus CD4 plus MMB3.19 plus anti–TNF- mAb
(32.1; P  .002 v ATBM plus MMB3.19). The results represent
pooled data (n  16 per group) from 2 similar experiments.
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allogeneic system, anti–TNF- mAb treatment effec-
tively blocked the development of CD4 T cell–me-
diated GVHD, but allowed a signiﬁcant level of GVL
activity to be generated.
DISCUSSION
In 1987, Piguet et al. [25] were the ﬁrst to show
the involvement of TNF- in GVHD, using a P3F1
model of MHC-incompatible HCT . They found that
injection of a neutralizing rabbit antimouse recombi-
nant TNF- IgG polyclonal antibody could signiﬁ-
cantly prevent skin and gut lesions, decrease mortality
rate (70% survival at day 80), and prevent weight loss
(a systemic indicator of GVHD severity). Others have
conﬁrmed Piguet’s observations by administering an-
ti–TNF- antibodies starting either before HCT or as
many as 7 days after [26-31]. In many of these studies,
the effectiveness of the treatment varied widely and
was complicated by varying sources of neutralizing
antibodies to TNF- and varying strain combinations
for the models themselves. In our own earlier experi-
ence, it was shown that the protective effects of a
polyclonal anti–TNF- antibody were restricted to
acute GVHD induced by CD4 T cells and were not
observed in a CD8-dependent model of GVHD [28].
This latter model, the B10.BR3CBA strain combi-
nation, which is MHC compatible but disparate for
multiple miHA, is the same as used in our current
studies, although we were now able to observe mod-
erate efﬁcacy on GVHD development with the
CNTO2213 anti–TNF- mAb (Figure 1). The dif-
ference in the observed results of this CD8-mediated
GVHD model is likely caused by the improved po-
tency of the mAb preparation and the enhanced phar-
macokinetic proﬁle of the chimeric rat/mouse anti-
body itself. Yet the earlier ﬁndings were still
consistent in regard to the relatively better effect of
anti–TNF- antibodies for CD4-mediated GVHD,
which is also supported by the current results in the
C3H3 (B6xC3H)F1 model (Figures 2 and 3). Treat-
ment with CNTO2213 had a much more dramatic
effect on survival when only donor CD4 T cells were
transplanted than with a donor inoculum of both CD4
and CD8 T cells.
A key question in relation to the effects of anti–
TNF- mAb treatment on GVHD development is
the level at which the cytokine blockade is having the
most impact. Three possibilities to consider are
whether (1) it is effective at blocking the initial con-
ditioning-related endothelial activation and upregula-
tion of adhesion molecules necessary for later T cell
homing into the target tissues; (2) it blocks the
TNF- produced by alloreactive donor T cells in the
peripheral lymphoid organs, which helps activate an-
tigen-presenting cells, which via IL-12 and more
TNF- production can then expand the initial stim-
ulation of more T cells and their orientation towards
Th1 cytokine production; or (3) it blocks the cytolytic
effects on target tissue of TNF- released locally by
either T cells, macrophages, or mast cells [28] partic-
ipating in the inﬂammatory process. Of course, all 3
effects of TNF- blockade may be occurring, because
the treatment regimen spans the time over which they
each might be critical. In this regard, evidence pro-
vided by the use of p55 TNF- receptor–deﬁcient
donor T cells in a GVHDmodel system suggested the
importance of TNF- in the alloreactive T cell re-
sponse [42]. In addition, recent observations in the
study of intestinal GVHD have indicated the impor-
tance of TNF-TNFR2 interactions for the develop-
ment of MHC class II–disparate disease mediated by
intestinal CD4 Th1 cytokine production [43]. How-
ever, TNF- did not seem to be critical for donor T
cell activation in the spleen. Further investigations
utilizing appropriate TNF-receptor–deﬁcient or
TNF-–nonproducing T cells and macrophages in
GVHD models could shed additional light on the
subject.
The above-mentioned potential effects of TNF-
blockade also can be critical to the development of
GVL activity, but conditions for successful develop-
ment of these responses may also be dependent on the
precise nature of the leukemia cells involved, where
they are located, and the effector mechanisms by
which the T cells are able to respond to them. First,
certain types of leukemia cells may lack MHC class II
expression (eg, many T cell leukemias) [44-46], which
would likely make them a poorer target of CD4-
mediated GVL effects, although indirect presentation
pathways can still operate for activation [47]. In mu-
rine models utilizing the MHC class II–negative mas-
tocytoma, P815, both Hill et al. [48] and Tsukada et
al. [49] have shown the importance of TNF- to what
is likely a CD8-mediated GVL response. In both of
these cases, the tumor cells were administered iv and,
therefore, the sites of tumor growth were likely to be
accessible to the donor lymphocytes as part of their
normal migration patterns through the lymphoid sys-
tem. This would suggest that TNF- was not required
for increased extravasation of effector CD8 T cells
through endothelial surfaces to reach the tumor cells.
Thus, TNF- may have been critical for CD8 activa-
tion, either directly or indirectly via antigen-present-
ing cell activation, or it was directly involved in the
cytolysis of tumor cells. Unlike P815 tumor cells, the
MMB3.19 leukemia cells express MHC class II and,
therefore, can directly interact with responding CD4
T cells. Previous studies with MMB3.19 and similar
myeloid leukemia models have shown that GVL re-
sponses can be mediated by either CD4 or CD8
donor T cells and that the former subset can effec-
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tively utilize either perforin- or FasL-dependent cy-
tolytic pathways for the effect [50,51].
A second reason why TNF- may not be critical
to the CD4 T cell–mediated GVL response is that in
the case of many leukemia cells of myeloid origin
(particularly monocytic and dendritic cell forms), they
have the capability of producing and secreting their
own TNF-, so they are less likely to be susceptible to
the cytolytic effects of the molecule. This is the situ-
ation for several of the murine myeloid leukemia cell
lines with which we have been working in our labo-
ratory, including the MMB3.19 cell line, and they are
completely resistant to any TNF-–mediated cytoly-
sis [52] (R.K., unpublished data). Furthermore, re-
turning to the important aspect of accessibility of the
GVL-mediating CD4 T cells to the MMB3.19 leu-
kemia cells, the tumor challenge was ip, and, thus, T
cell extravasation may be somewhat different than that
required for the immunopathogenesis of GVHD le-
sions in target organs. In this regard, in other murine
models, IL-15 has been found to be the dominant
promoter of endothelial cell changes that enhance T
cell entry into the peritoneal extralymphoid tissues
[53].
As mentioned earlier, the role of TNF- in the
development of GVHD appeared to be more critical
for CD4- rather than CD8-mediated disease in the
models that were tested. This difference may be re-
lated to the underlying type of systemic disease that
develops. The kinetics of the CD4-mediated GVHD
response in the C3H3(B6xC3H)F1model is much
more rapid (the majority of the mice succumbed by 11
days) than the CD8-mediated disease in the
B10.BR3CBA strain combination (mice died be-
tween 13 and 40 days). The CD4-mediated form of
disease presents as a strong intestinal GVHD reaction,
and the observed effect of TNF- inhibition in this
model is consistent with previous observations related
to the dependence on TNF- interactions for intes-
tinal GVHD in the B63bm12 MHC class II–dispa-
rate model [43], and lipopolysaccharide–induced
TNF- release in a similar C3H3(B6xC3H)F1model
[54]. However, the CD8-mediated B10.BR3 CBA
GVHD response involves a much more widespread
distribution of target tissue–related inﬂammation and
injury with marked immunopathology in the liver,
gut, skin, and lymphoid organs developing over the
ﬁrst several weeks after transplantation [28]. There-
fore, it would seem that either some of these patho-
logic effects are independent of TNF- or that
enough fatal injury was still able to develop in some
mice after cessation of anti–TNF- mAb treatments
on day 12 posttransplantation. Further pathologic
analysis is necessary in this model to discern the effects
of the TNF- blockade on GVHD at the level of the
target organs.
In the allogeneic C3H3(B6xC3H)F1model, the
anti–TNF- mAb treatment was clearly effective in
blocking the CD4-mediated GVHD, while still allow-
ing a signiﬁcant GVL response to develop against the
MMB3.19 leukemia cells (Figure 8). However, the
GVL effect in this situation was not able to sustain
meaningful long-term survival of the recipients, with
all animals eventually succumbing to tumor burden.
Although transplantation of higher dosages of donor
T cells would likely increase the long-term survival
rate, the model is counterbalanced by the limitation
that increasing the donor T cell number would also
signiﬁcantly increase the GVHD potential of those
cells when given at time of marrow transplant, beyond
the level that can be controlled by the anti–TNF-
mAb treatment. The possible solution to this problem
may be in the use of a delayed donor lymphocyte
infusion (DLI) approach. In the clinical situation, DLI
has been found to be effective in preventing or revers-
ing leukemic relapse and EBV-induced lymphoprolif-
erative disease in patients with poor reconstitution of
donor T cells [55-57]. In murine models, it has been
found that delaying the infusion of donor T cells to at
least 2 weeks after bone marrow transplantation helps
avoid the “cytokine storm” associated with the pre-
conditioning irradiation exposure of the recipients,
which is inductive for GVHD [58,59]. Delay also
allows for both the loss of host antigen-presenting
cells [60] and the de novo development of regulatory
CD25 T cells [61], both of which can limit the
induction of GVHD. Therefore, higher doses of do-
nor T cells can potentially be administered as a DLI
with less risk of GVHD, although GVHD is still
clearly the most dominant complication of the ap-
proach [55,56,62]. It remains to be seen whether
TNF- blockade will affect a DLI-mediated GVL
effect; this is currently under study.
We have found that a chimeric rat/mouse anti–
TNF- mAb could reduce the development of
GVHD in murine models, with a more signiﬁcant
effect in CD4- rather than CD8-mediated disease.
However, in the CD4 model, the development of
GVL responses was unhindered by anti–TNF- mAb
treatment, and, thus, this approach may serve as a
potential means for separating out deleterious from
beneﬁcial effects of donor T cell reactive capabilities.
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